Alzheimer’s disease is a devasting condition that affects the brain, causing severe memory loss.
Researchers have been searching for effective treatments to slow down or halt the progression of the disease for many years.
Finally, a new drug called TB006 is showing massive potential in improving the symptoms of Alzheimer’s.
This promising treatment is now available at our clinic—the first in Florida to offer this experimental therapy.
Here, we explain what TB006 Alzheimer is, how this breakthrough Alzheimer’s treatment works, and what this can mean for patients and caregivers.
TB006 is a new experimental drug that can reduce the buildup of amyloid plaques in the brain.
Amyloid plaques are predominantly made from proteins called “beta-amyloid” that clump together in the brains of people with Alzheimer’s.
The plaques disrupt communication between the brain cells (neurons) and cause inflammation, which leads to cognitive symptoms like memory loss.
By stopping the beta-amyloid proteins from clumping together to form plaques, TB006 can reverse the symptoms of Alzheimer's.
It allows the neurons to communicate normally, improving cognition.
TB006 works by binding to a protein called Galectin-3, found in abnormally high levels in the brains of people with Alzheimer’s disease.
Galectin-3 binds to beta-amyloids, acting as a glue that causes these proteins to clump together and form amyloid plaques—but Galectin-3 cannot bind to TB006 and beta-amyloid at the same time.
By binding to Galectin-3, TB006 stops Galactin-3 from acting as a glue.
By doing so, TB006 has the power to:
TB006 is considered a breakthrough therapy for Alzheimer’s disease for several reasons:
We are proud to announce that Universal Neurological Care is the first in Northeast Florida to infuse TB006 into an Alzheimer's patient.
This milestone represents a significant step forward in the fight against this debilitating disease.
Our commitment to providing cutting-edge treatments is at the core of our mission to improve the lives of people affected by neurological disorders.
By exploring new treatment options, we can work together to combat Alzheimer's disease and offer a brighter future for patients and their families.
Stay tuned for more updates on TB006 and other exciting developments in neurological care.
Q: What are the results of TB006?
A: The results of TB006 are extremely promising. Alzheimer’s News Today reports that three months of TB006 reserved symptoms in almost half of patients, improving memory and cognitive function.
Q: What is Galectin-3 in Alzheimer’s disease?
A: Galectin-3 is a protein that acts as a glue, causing beta-amyloid proteins to clump together in the brain as plaques. TB006 targets Galectin-3, preventing it from sticking these other proteins together.
Q: Is TB006 safe?
A: Yes, TB006 is safe. Clinical trials on healthy individuals showed the drug was safe. The safety profile was then tested in Alzheimer’s patients, and no treatment-related adverse effects were found.
With such promising results, TB006 is an encouraging new advancement in the fight against Alzheimer's disease.
If you or a loved one is affected by Alzheimer's disease and is interested in learning more about TB006, please contact our clinic. Our expert medical team can administer this agent to candidates who meet eligibility criteria.
Universal Neurological Care is here to provide information, support, and guidance as you navigate this challenging journey.
